Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds

European Journal of Endocrinology, Supplement

Volumn 156, Issue 1, 2007, Pages

  Zatelli, Maria Chiara ^a   Ambrosio, Maria Rosaria ^a   Bondanelli, Marta ^a   Degli Uberti, Ettore C ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23120; BMI 2310; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; OCTREOTIDE; PASIREOTIDE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ACIDOPHILE; ACROMEGALY; CELL PROLIFERATION; CELL SIZE; CELL VIABILITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CUSHING SYNDROME; DNA SYNTHESIS; DRUG EFFECT; DRUG INHIBITION; FIBROSING ALVEOLITIS; HUMAN; HYPOPHYSIS ADENOMA; NECROSIS; NELSON SYNDROME; NONFUNCTIONING PITUITARY ADENOMA; NONHUMAN; PROLACTINOMA; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT DURATION; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ANIMALS; CELL PROLIFERATION; DOPAMINE AGONISTS; HUMANS; PITUITARY NEOPLASMS; RATS; RECEPTORS, DOPAMINE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 34249022640     PISSN: 08044635     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02352     Document Type: Conference Paper

References (62)

1. Brazeau P & Guillemin R. Somatostatin: newcomer from the hypothalamus. New England Journal of Medicine 1974 290 963-964.
2. Giustina G, Peracchi M, Reschini E, Panerai AE & Pinto M. Dose-response study of the inhibiting effect of somatostatin on growth hormone and insulin secretion in normal subjects and acromegalic patients. Metabolism 1975 24 807-815.
3. Hall R, Snow M, Scanlon M, Mora B & Gomez-Pan A. Pituitary effects of somatostatin. Metabolism 1978 27 (Suppl 1) 1257-1262.
4. Culler MD, Taylor JE & Moreau JP. Somatostatin receptor subtypes: targeting functional and therapeutic specificity. Annals of Endocrinology 2002 63 2S5-2S12.
5. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, Buscail L & Susini C. Signal transduction of somatostatin receptors negatively controlling cell proliferation. Journal of Physiology 2000 94 205-210.
6. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Serially AV, Vaysse N & Susini C. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. PNAS 1995 92 1580-1584.
7. Sharma K, Patel YC & Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Molecular Endocrinology 1996 10 1688-1696.
8. Koper JW, Hofland LJ, van Koetsveld PM, den Holder F & Lamberts SW. Desensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion. Cancer Research 1990 50 6238-6242.
9. Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC & Lamberts SW. Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. Endocrinology 1992 131 571-577.
10. Panetta R & Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 1995 56 333-342.
11. Thapar K, Kovacs KT, Stefaneanu L, Scheithauer BW, Horvath E, Lloyd RV, Li J & Laws ER Jr. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clinic Proceedings 1997 72 893-900.
12. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F & Giovanelli M. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2001 86 5194-5200.
13. Cap J, Cerman J, Nemecek S, Marekova M, Hana V & Frysak Z. The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas. Journal of Clinical Neurosciences 2003 10 444-448.
14. Ezzat S, Horvath E, Harris AG & Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1994 79 113-118.
15. Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews 1992 13 220-240.
16. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1856-1863.
17. Renner U, Mojto J, Lange M, Muller OA, von Werder K & Stalla GK. Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinolology 1994 130 80-91.
18. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD & Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. Journal of Clinical Endocrinology and Metabolism 2001 86 2976-2981.
19. Dasgupta P, Singh AT & Mukherjee R. Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. Biochemical Biophysical Research Communications 1999 259 379-384.
20. Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti JL, Spaziante R, Giusti M & Schettini G. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clinical Endocrinology 2003 59 115-128.
21. Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Luciani P, Peri A, Mantovani G, Bosari S, Beck-Peccoz P, Spada A & Lania A. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocrine-Related Cancer 2006 13 955-962.
22. Luciani P, Gelmini S, Ferrante E, Lania A, Benvenuti S, Baglioni S, Mantovani G, Cellai I, Ammannati F, Spada A, Serio M & Peri A. Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2005 90 6156-6161.
23. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U & Stalla GK. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 2006 66 1576-1582.
24. Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G & Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 1999 141 396-408.
25. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D & Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nature Reviews. Drug Discovery 2003 2 999-1017.
26. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A & degli Uberti EC. SHP-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 2005 146 2692-2698.
27. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000 288 154-157.
28. Culler MD. Evolving concepts in the quest for advanced therapeutic analogues of somatostatin. Digestive and Liver Disease 2004 36(Suppl 1) S17-S25.
29. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD & degli Uberti EC. Somatostatin receptor subtype 1 selective activation in human growth hormone- and prolactin-secreting pituitary adenomas: effects on cell viability, growth hormone and prolactin secretion. Journal of Clinical Endocrinology and Metabolism 2003 88 2797-2802.
30. Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF & Annunziato L. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 2004 79 142-148.
31. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L & degli Uberti EC. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin A secretion and on cell viability in human non-functioning pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 5181-5188.
32. Oppizzi G, Cozzi R, Dallabonzana D, Orlandi P, Benini Z, Petroncini M, Attanasio R, Milella M, Banfi G & Possa M. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors. Journal of Endocrinological Investigation 1998 21 512-519.
33. Andersen M, Bjerre P, Schroder HD, Edal A, Hoilund-Carlsen PF, Pedersen PH & Hagen C. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clinical Endocrinology 2001 54 23-30.
34. Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B & Lombardi G. New medical approaches in pituitary adenomas. Hormone Research 2000 53 (Suppl 3) 76-87.
35. Gasperi M, Petrini L, Pilosu R, Nardi M, Marcello A, Mastio F, Bartalena L & Martino E. Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. Journal of Endocrinological Investigation 1993 16 541-543.
36. Wood WM, Sarapura VD, Dowding JM, Woodmansee WW, Haakinson DJ, Gordon DF & Ridgway EC. Early gene expression changes preceding thyroid hormone-induced involution of a thyrotrope tumor. Endocrinology 2002 143 347-359.
37. Woodmansee WW, Kerr JM, Tucker EA, Mitchell JR, Haakinson DJ, Gordon DF, Ridgway EC & Wood WM. The proliferative status of thyrotropes is dependent on modulation of specific cell cycle regulators by thyroid hormone. Endocrinology 2006 147 272-282.
38. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S, Czirjak S, Hanzely Z, Nagy GM, Goth MI, Grossman AB & Korbonits M. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. European Journal of Endocrinology 2006 155 371-379.
39. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T & Fletcher WS. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. Journal of Surgical Research 1993 55 446-450.
40. Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low MJ & Becu-Villalobos D. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knock-out female mice. Endocrinology 2005 146 2952-2962.
41. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R & Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 2001 14 329-336.
42. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK & Low MJ. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 1997 19 103-113.
43. Saiardi A, Bozzi Y, Baik JH & Borrelli E. Antiproliferative role of dopamine: loss of D2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 1997 19 115-126.
44. Bosse R, Fumagalli F, Jaber M, Giros B, Gainetdinov RR, Wetsel WC, Missafe C & Caron MG. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron 1997 19 127-138.
45. Iaccarino C, Samad TK, Mathis C, Kercret H, Picetti R & Borrelli E. Control of lactotrope proliferation by dopamine: essential role of signalling through D2 receptors ERKs. PNAS 2002 99 14530-14535.
46. Sarkar DK, Chaturvedi K, Oomizu S, Boyadjieva NI & Chen CP. Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes. Endocrinology 2005 146 4179-4188.
47. Enjalbert A & Bockaert J. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary. Molecular Pharmacology 1983 23 576-584.
48. Martinez de la Escalera G, Guthrie J & Weiner RI. Transient removal of dopamine potentiates the stimulation of prolactin release by TRH but not VIP: stimulation via Ca2+/protein kinase C pathway. Neuroendocrinology 1988 47 38-45.
49. Ben-Jonathan N & Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews 2001 22 724-763.
50. Takeuchi Y, Miyamoto E & Fukunaga K. Activation of the rat dopamine D2 receptor promoter by mitogen-activated protein kinase and Ca2+/calmodulin-dependent protein kinase II pathways. Journal of Neurochemistry 2002 83 784-796.
51. Bevan JS & Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clinical Endocrinology 1986 25 561-572.
52. Liuzzi A, Tassi V, Pirro MT, Zingrillo M, Ghiggi MR, Chiodini I, Oppizzi G & Barberis M. Nonfunctioning adenomas of the pituitary. Metabolism 1996 45 80-82.
53. Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M, Weindl A & Stalla GK. Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1368-1375.
54. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D. Jaquet P, Kordon C & Enjalbert A. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994 60 314-322.
55. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS & Baik JH. Anti-proliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Molecular and Cellular Endocrinology 2003 206 49-62.
56. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ & Lamberts SW. Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 2452-2462.
57. Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G & Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. Journal of Endocrinological Investigation 1999 22 860-865.
58. T'Sjoen G, Defeyter I, Van De Saffele J, Rubens R & Vandeweghe M. Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline. Journal of Endocrinological Investigation 2002 25 172-175.
59. Yin D, Kondo S, Takeuchi J & Morimura T. induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Letters 1994 339 73-75.
60. Illouz F, Dubois-Ginouves S, Laboureau S, Rohmer V & Rodien P. Use of cabergoline in persisting Cushing's disease. Annals of Endocrinology 2006 67 353-356.
61. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA & Klibanski A. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2006 91 4482-4488.
62. Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ, Culler MD & Pawlikowski M. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically nonfunctioning" pituitary adenomas in vitro. Life Sciences 2006 78 689-693.